Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hypoxia Study Confirms Accuracy of Movano Ring for SpO2 & Heart Rate Monitoring - Medical Product Outsourcing
OEM News

Hypoxia Study Confirms Accuracy of Movano Ring for SpO2 & Heart Rate Monitoring

Vital health metric demonstrates wearable’s potential to properly track heart health and detect possible illnesses.

Movano Inc., a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices, has completed a study with the University of California San Francisco (UCSF) to assess the accuracy of the Movano Ring’s blood oxygen saturation (SpO2) and heart rate data.
 
With results that exceeded the requirements of the industry standard used by FDA for evaluating SpO2 devices, this successful study is a promising step toward the company’s goal to provide medically-validated data to consumers and healthcare professionals.

About The Study

The study was conducted on seven subjects of mixed genders and ethnicities. Wearing a Movano Ring prototype and reference devices within a controlled environment, each participant’s oxygen levels were driven down to as low as 70 percent and then back up to 100 percent to test the accuracy of Movano’s device during mild, moderate and severe hypoxia. The prototype also measured heart rate during this time and participants’ heart rate varied from 60 to 120 beats per minute as they were being deprived of oxygen.
 
In comparing the overall accuracy of the Ring’s data with that of the reference devices, the Movano Ring resulted in a 2% margin of error, well below the FDA’s 4% requirement for SpO2. In addition, the Ring also estimated heart rate with accuracy commensurate with the FDA’s standards.
 
As Movano eyes its first FDA submission, validating the device’s ability to measure blood oxygen levels, heart rate and other vitals is a top priority for the company. Based on the positive results from this study, Movano plans to conduct a larger pivotal study for the FDA submission later this year.
 
“The FDA has a high threshold for accuracy and requires an extensive investment by any company to prepare to meet these standards. This hypoxia study is a promising display of the quality metrics our ring can deliver,” said John Mastrototaro, CEO of Movano. “While this outcome is an exciting step toward the FDA submission, what it really means for consumers and healthcare providers is we’re one step closer to being able to trust and utilize the ring data in a meaningful way.”

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters